Stock listing

NASDAQ:CTOR Citius Oncology, Inc. Stock

Home listing (NASDAQ) of Citius Oncology, Inc.

Follow Citius Oncology, Inc. into a list and get an email when it puts out news.

Share price · NASDAQ:CTOR

$0.504 USD -0.054 (-9.7%)

Close on Nov 20, 2026

Past year -55.4% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.502 – $0.570 USDNov 20, 2026
Volume
52,634 sharesNov 20, 2026
Market cap
$53.25M USDAt the close on Nov 20, 2026 · price × 105.8M shares outstanding
52-week range
$0.491 – $1.830 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$83,583 USDMedian day 83,079 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Citius Oncology, Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:CTOR · Home$0.504 USD-0.054 (-9.7%)52,634$0.570$0.570$0.502$0.557Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:CTOR · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.504-0.054-9.7%$0.570$0.570$0.50252,634
$0.557+0.010+1.8%$0.545$0.572$0.540152,055
$0.548+0.013+2.4%$0.552$0.595$0.548177,306
$0.535-0.039-6.8%$0.559$0.576$0.52583,079
$0.574+0.051+9.9%$0.522$0.591$0.522224,751
$0.522-0.033-5.9%$0.540$0.567$0.52073,333
$0.555-0.008-1.4%$0.554$0.573$0.54544,832
$0.563+0.013+2.4%$0.562$0.563$0.53884,896
$0.550+0.040+7.9%$0.520$0.585$0.520106,688
$0.510+0.009+1.9%$0.541$0.541$0.502195,332
$0.500-0.047-8.6%$0.548$0.577$0.494145,279
$0.547-0.003-0.5%$0.556$0.595$0.54079,857
$0.550-0.044-7.4%$0.608$0.622$0.547188,031
$0.594+0.040+7.2%$0.589$0.694$0.554378,696
$0.554+0.025+4.6%$0.527$0.563$0.500283,279
$0.530-0.047-8.2%$0.580$0.607$0.506193,082
$0.577-0.034-5.6%$0.629$0.629$0.57191,806
$0.611+0.015+2.6%$0.634$0.646$0.571134,810
$0.596+0.016+2.8%$0.612$0.689$0.539874,207
$0.580-0.120-17.2%$0.720$0.720$0.51070,533
$0.700-0.001-0.1%$0.729$0.730$0.65538,020
$0.700+0.029+4.4%$0.705$0.760$0.65222,886
$0.671-0.039-5.5%$0.730$0.747$0.66097,444
$0.710-0.058-7.5%$0.756$0.760$0.70040,000
$0.768+0.022+2.9%$0.770$0.770$0.75011,700
$0.746-0.038-4.8%$0.760$0.770$0.74511,000
$0.784-0.008-1.0%$0.811$0.811$0.75027,600
$0.792-0.021-2.6%$0.800$0.844$0.74396,700
$0.813-0.027-3.2%$0.860$0.860$0.78067,900
$0.840+0.005+0.6%$0.842$0.880$0.80071,000
$0.835-0.016-1.9%$0.870$0.870$0.82056,400
$0.851+0.001+0.1%$0.847$0.901$0.847105,500
$0.850-0.024-2.7%$0.858$0.920$0.812109,800
$0.874-0.076-8.0%$0.930$0.930$0.86085,500
$0.950-0.030-3.1%$0.999$1.050$0.914208,400
$0.980-0.030-3.0%$1.070$1.070$0.94299,600
$1.010-0.040-3.8%$1.090$1.090$1.00096,700
$1.050+0.020+1.9%$1.025$1.130$1.000186,000
$1.030-0.020-1.9%$1.040$1.080$1.02043,600
$1.0500.0000.0%$1.070$1.070$1.02026,700
$1.050+0.040+4.0%$1.030$1.080$1.00740,700
$1.010-0.060-5.6%$1.050$1.070$0.98555,800
$1.070+0.025+2.4%$1.000$1.120$1.000117,000
$1.045-0.095-8.3%$1.150$1.150$1.030152,200
$1.140+0.120+11.8%$1.050$1.155$1.010336,900
$1.020+0.066+6.9%$0.970$1.050$0.920189,200
$0.954+0.098+11.4%$0.890$0.984$0.853184,400
$0.856-0.084-8.9%$0.950$0.978$0.850118,000
$0.940+0.022+2.4%$0.920$0.988$0.91569,200
$0.918+0.008+0.9%$0.890$0.950$0.890138,300
$0.910-0.030-3.2%$0.920$0.940$0.86847,900
$0.940+0.011+1.2%$0.910$0.960$0.85856,400
$0.929+0.069+8.0%$0.913$0.940$0.872220,800
$0.860+0.068+8.6%$0.767$0.882$0.75054,700
$0.792+0.014+1.8%$0.800$0.800$0.77813,900
$0.778+0.028+3.7%$0.735$0.800$0.72512,100
$0.750-0.013-1.7%$0.770$0.777$0.72516,600
$0.763-0.013-1.7%$0.820$0.820$0.75338,700
$0.776-0.014-1.8%$0.800$0.800$0.75421,700
$0.790+0.003+0.4%$0.828$0.830$0.7908,600
$0.787-0.023-2.8%$0.791$0.820$0.75217,000
$0.810+0.060+8.0%$0.705$0.818$0.705134,100
$0.750+0.006+0.8%$0.759$0.760$0.72216,600
$0.744-0.015-2.0%$0.721$0.755$0.72113,400
$0.759+0.006+0.8%$0.752$0.773$0.71052,100
Ticker
NASDAQ:CTOR
Asset type
Stock
Sector
Health care
Industry
Pharmaceuticals
Exchange
NASDAQ
Currency
USD

What changed lately

Latest news

All Citius Oncology, Inc. news

Citius Oncology, Inc. on 6ix

Sector
Health care
Industry
Pharmaceuticals
News releases
27 in the last 12 months · 59 in all · newest Nov 11, 2026 · oldest 2023
Decks
4 decks · latest Dec 1, 2025

Where Citius Oncology, Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:CTOR · Home listing · This pageNASDAQUnited StatesUSD
BOATS:CTORBOATSUnited StatesUSD

Valuation

Price/book 1.3× against a median of 1.1×: 7th lowest of 10 Pharmaceuticals companies shown. Statements: 4 quarters to Jun 30, 2026 · price Nov 20, 2026

Enterprise value
$36.69M USD
P/E
Loss
EV/sales
No revenue
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
1.3×
Gross margin
No revenue
Operating margin
No revenue
Net margin
No revenue
Debt to equity
0.0×
Beta vs S&P 500
1.66

Pharmaceuticals: the 10 companies nearest in size, of 492 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Citius Oncology, Inc. · NASDAQ:CTORUS$53.25MUS$36.69Mn/an/an/a1.3×n/a0.0×1.66
Korea Pharma Co., Ltd. · KRX:032300US$59.92MUS$47.49Mn/a0.7×13.4×1.1×−0.8%0.2×n/a
High Tech Pharm. Co., Ltd. · KRX:106190US$59.61MUS$57.37M6.7×1.1×4.3×0.6×17.2%0.0×n/a
Valiant Laboratories Ltd. · NSE:VALIANTLABUS$55.63MUS$55.72M31.8×1.4×13.5×1.6×4.3%0.1×n/a
Samik Pharm Co., Ltd. · KRX:014950US$52.45MUS$28.27Mn/a0.6×12.0×1.0×−2.4%0.0×n/a
Chi Sheng Pharma & Biotech Co., Ltd. · TPEX:4111US$49.92MUS$35.59M8.7×0.8×4.3×1.2×13.3%0.0×n/a
Biome Australia Ltd · ASX:BIOUS$49.01MUS$48.63M20.5×3.1×34.2×7.9×15.1%0.3×n/a
Shivalik Rasayan Ltd · NSE:SHIVALIKUS$48.94MUS$48.94M33.2×1.2×6.4×0.8×3.6%0.0×n/a
Verrica Pharmaceuticals Inc. · NASDAQ:VRCAUS$47.07MUS$45.98Mn/a2.0×n/an/a−189.2%n/a2.03
Albert David Ltd · NSE:ALBERTDAVDUS$46.97MUS$19.58M15.1×0.5×5.1×1.0×7.6%0.1×n/a
LTR Pharma Limited · ASX:LTPUS$46.45MUS$33.44Mn/a275×n/a3.5×n/a0.0×n/a
Median of the othersUS$49.47MUS$46.74M17.8×1.2×9.2×1.1×4.3%0.0×2.03

Forecasts

1 buy · Analysts' consensus from EODHD, read Nov 17, 2026. Not 6ix's view and not investment advice.

Price target
4.00 USD · Analysts' mean
EPS, year to Sep 2026
-0.50 · 1 analyst
Revenue, year to Sep 2026
10.39M · 1 analyst

Team and board

Officers

OfficerRole
Myron HolubiakSecretary

Board

DirectorRole
Leonard MazurChairman
Carol WebbDirector
Dennis M. McGrathDirector
Eugene HolukaDirector
Joel MayersohnDirector
Jonathan PeriDirector
Myron HolubiakSecretary
Robert SmithDirector
Suren DutiaDirector

Events

Next results
Dec 22, 2026 (expected)
QuarterResultsShare move
Q3 2026Aug 14, 2026 · After close−18.7%
Q2 2026May 15, 2026 · After close−13.9%
Q1 2026Feb 13, 20260.0%
Q4 2025Dec 23, 2025 · After close−9.8%
Q3 2025Aug 12, 2025 · After close+5.9%
Q2 2025May 14, 2025 · After close−0.6%
Q1 2025Feb 17, 2025−5.6%
Q4 2024Dec 30, 2024+10.6%
Q3 2024Aug 28, 2024−3.3%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (December 2025)Investor deck19 slidesDec 1, 2025
Investor Presentation (October 2025)Investor deck19 slidesOct 23, 2025
Investor Presentation (February 2025)Investor deck28 slidesFebruary 2025
SPAC Merger (October 2023)SPAC merger33 slidesOct 24, 2023

Open Decks

Financings

RaiseDate
Senior secured term loan with warrants
Announced: US$10M–US$25M · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Buyers: Avenue Venture Opportunities Fund II, L.P. (up to $25 million senior secured term loan credit facility)
Use of proceeds: LYMPHIR commercialization (sales force, market access, medical affairs, supply chain), working capital and general corporate purposes
May 5, 2026
Warrant exercise of exercise of outstanding warrants for common stock
Announced: about US$11.5M · US$0.9 a share · Warrants at US$0.9 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: LYMPHIR commercialization (sales force, market access, medical affairs, supply chain), working capital and general corporate purposes
May 5, 2026
Registered direct offering of common stock with unregistered warrants
Closed: US$1.09 a share · Warrants at US$1.09 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR, working capital and general corporate purposes
Dec 10, 2025
Private placement of common stock (or pre-funded warrants) and warrants
Closed: US$1.09 a share · Warrants at US$1.09 for 60 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Support the commercial launch of LYMPHIR, working capital and general corporate purposes
Dec 10, 2025
Registered direct offering of common stock with accompanying unregistered warrants
Closed: US$9M raised · US$1.75 a share · ½ warrant at US$1.84 for 66 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Sep 10, 2025
Public offering of common stock and warrants
Closed: US$9M raised · US$1.32 a share · Warrants at US$1.32 for 60 months · Maxim Group LLC
Dealers: Maxim Group LLC (lead)
Use of proceeds: Commercialization of LYMPHIR, including license milestone and royalty payments, plus working capital and general corporate purposes
Jul 17, 2025

Open Financings · Read by 6ix AI from the company's releases

IPO

Went public as TenX Keane Acquisition, a blank check company (SPAC). Priced at US$10.00 a unit on Oct 13, 2022.

Price
US$10.00 a unit
Units offered
6,000,000 units
Offering size
US$60 million
Underwriters' option
Up to 900,000 more units
Listing
TENKU on the Nasdaq Global Market
Underwriter
Maxim Group LLC
Units delivered
On or about Oct 18, 2022

Steps

StepWhen
Filed publiclyMay 19, 2021
Amended 8 timesNewest Sep 12, 2022
Shares registered with an exchangeOct 13, 2022
Declared effective by the SECOct 13, 2022
Final prospectus, with the priceOct 14, 2022

Open IPO · From the cover of the final prospectus (424B4) filed Oct 14, 2022

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2024FY2023FY2023
Research and development6.42M4.93M4.24M
Operating income-23.5M-20.6M-1.01M-138.1K
Interest expense218.0K
Income before tax-23.7M-20.6M-12.1M
Income tax1.06M576.0K576.0K
Net income-24.8M-21.1M2.42M-12.7M380.8K
Earnings per share, basic-0.34-0.310.27-0.190.12
Earnings per share, diluted-0.34-0.310.27-0.190.12

Balance sheet

LineFY2025FY2024FY2024FY2023FY2023
Cash and equivalents3.92M11232.7K26.5K289.2K
Inventory22.3M8.27M
Current assets27.5M11.0M58.2K7.73M377.3K
Total assets100.9M84.4M72.6M47.7M68.2M
Accounts payable13.2M3.71M1.29M
Current liabilities49.5M32.7M2.05M21.0M31.8K
Total liabilities56.1M38.2M22.2M
Shareholders' equity44.9M46.1M22.7M25.5M345.5K
Shares outstanding83.5M71.6M2.34M67.5M2.42M

Cash flow

LineFY2025FY2024FY2024FY2023
Cash from operations-5.49M126.4K-601.3K-48.0K
Cash from investing-5.75M-5.00M-1.32M-67.3M
Cash from financing15.2M4.87M1.66M67.7M
Change in cash3.92M112-256.4K289.2K

Open Financials

Filings

FilingDateTypeFiled with
SCHEDULE 13G/A · Big-stake notice, amendedNov 16, 2026Big-stake noticeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 13, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
Show 200 filings
FilingDateTypeFiled with
4 · Change in ownershipNov 12, 2026Insider tradeSEC
4 · Change in ownershipNov 12, 2026Insider tradeSEC
8-K · Current reportNov 4, 2026Current reportSEC
8-K · Current reportOct 26, 2026ResultsSEC
8-K · Current reportOct 23, 2026Current reportSEC
8-K · Current reportSep 29, 2026Meeting outcomeSEC
ARS · Annual report to shareholdersAug 26, 2026Annual reportSEC
DEF 14A · Proxy statementAug 26, 2026Meeting noticeSEC
3 · Initial statement of ownershipAug 14, 2026Insider tradeSEC
424B3 · ProspectusAug 14, 2026Offer documentSEC
10-Q · Quarterly reportAug 14, 2026Quarterly reportSEC
8-K · Current reportAug 14, 2026ResultsSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 14, 2026Big-stake noticeSEC
8-K · Current reportAug 12, 2026Management or board changeSEC
424B3 · ProspectusAug 5, 2026Offer documentSEC
8-K · Current reportAug 5, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveJun 8, 2026Other filingsSEC
SCHEDULE 13D/A · Big-stake notice, amendedJun 4, 2026Big-stake noticeSEC
CORRESP · Letter to the SECJun 3, 2026Other filingsSEC
UPLOAD · Letter from the SECJun 3, 2026Other filingsSEC
424B3 · ProspectusJun 1, 2026Offer documentSEC
8-K · Current reportJun 1, 2026Current reportSEC
DEF 14CMay 29, 2026Meeting noticeSEC
S-3 · Registration statementMay 29, 2026Offer documentSEC
424B3 · ProspectusMay 22, 2026Offer documentSEC
PRE 14CMay 19, 2026Meeting noticeSEC
8-K · Current reportMay 15, 2026ResultsSEC
10-Q · Quarterly reportMay 15, 2026Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 15, 2026Big-stake noticeSEC
424B3 · ProspectusMay 6, 2026Offer documentSEC
8-K · Current reportMay 6, 2026Material contractSEC
424B3 · ProspectusMay 5, 2026Offer documentSEC
8-K · Current reportApr 29, 2026Current reportSEC
8-K · Current reportApr 28, 2026Current reportSEC
8-K · Current reportMar 31, 2026Current reportSEC
8-K · Current reportMar 10, 2026Current reportSEC
8-K · Current reportMar 4, 2026Current reportSEC
EFFECT · Notice that a registration is effectiveMar 3, 2026Other filingsSEC
POS AM · Amendment to an effective registrationFeb 20, 2026Offer documentSEC
SCHEDULE 13G/A · Big-stake notice, amendedFeb 17, 2026Big-stake noticeSEC
8-K · Current reportFeb 13, 2026ResultsSEC
10-Q · Quarterly reportFeb 13, 2026Quarterly reportSEC
DEF 14CJan 29, 2026Meeting noticeSEC
PRE 14CJan 20, 2026Meeting noticeSEC
EFFECT · Notice that a registration is effectiveJan 13, 2026Other filingsSEC
CORRESP · Letter to the SECJan 9, 2026Other filingsSEC
UPLOAD · Letter from the SECJan 9, 2026Other filingsSEC
S-3 · Registration statementJan 5, 2026Offer documentSEC
8-K · Current reportDec 23, 2025ResultsSEC
10-K · Annual reportDec 23, 2025Annual reportSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 22, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedDec 17, 2025Big-stake noticeSEC
8-K · Current reportDec 10, 2025Material contractSEC
424B5 · ProspectusDec 9, 2025Offer documentSEC
8-K · Current reportDec 1, 2025Current reportSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
4/A · Change in ownership, amendedDec 1, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeNov 14, 2025Big-stake noticeSEC
8-K · Current reportOct 27, 2025Management or board changeSEC
8-K · Current reportOct 23, 2025Current reportSEC
DEF 14A · Proxy statementSep 26, 2025Meeting noticeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
4 · Change in ownershipSep 23, 2025Insider tradeSEC
S-8 · Registration statement for employee plansSep 19, 2025Offer documentSEC
8-K · Current reportSep 19, 2025Management or board changeSEC
SCHEDULE 13D/A · Big-stake notice, amendedSep 12, 2025Big-stake noticeSEC
424B3 · ProspectusSep 10, 2025Offer documentSEC
8-K · Current reportSep 10, 2025Material contractSEC
424B5 · ProspectusSep 10, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveSep 5, 2025Other filingsSEC
CORRESP · Letter to the SECSep 2, 2025Other filingsSEC
S-3 · Registration statementSep 2, 2025Offer documentSEC
UPLOAD · Letter from the SECAug 22, 2025Other filingsSEC
DRS · Draft registration statementAug 20, 2025Offer documentSEC
8-K · Current reportAug 18, 2025Current reportSEC
424B3 · ProspectusAug 18, 2025Offer documentSEC
8-K · Current reportAug 12, 2025ResultsSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
4 · Change in ownershipAug 7, 2025Insider tradeSEC
SCHEDULE 13D/A · Big-stake notice, amendedJul 25, 2025Big-stake noticeSEC
8-K · Current reportJul 18, 2025Material contractSEC
EFFECT · Notice that a registration is effectiveJul 17, 2025Other filingsSEC
424B4 · ProspectusJul 16, 2025Offer documentSEC
CORRESP · Letter to the SECJul 15, 2025Other filingsSEC
S-1/A · Registration statement, amendedJul 14, 2025Offer documentSEC
S-1 · Registration statementJul 14, 2025Offer documentSEC
8-K · Current reportJun 27, 2025Current reportSEC
8-K · Current reportJun 17, 2025Current reportSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
8-K · Current reportMay 14, 2025ResultsSEC
UPLOAD · Letter from the SECMay 1, 2025Other filingsSEC
DRS · Draft registration statementApr 28, 2025Offer documentSEC
8-K · Current reportApr 25, 2025Current reportSEC
8-K · Current reportApr 3, 2025Material contractSEC
DEFA14CFeb 24, 2025Other filingsSEC
DEF 14CFeb 24, 2025Meeting noticeSEC
8-K · Current reportFeb 14, 2025Current reportSEC
10-Q · Quarterly reportFeb 14, 2025Quarterly reportSEC
PRE 14CFeb 12, 2025Meeting noticeSEC
8-K · Current reportFeb 6, 2025Current reportSEC
10-K/A · Annual report, amendedJan 27, 2025Annual reportSEC
8-K · Current reportJan 7, 2025Current reportSEC
8-K · Current reportJan 6, 2025Current reportSEC
8-K · Current reportDec 27, 2024ResultsSEC
10-K · Annual reportDec 27, 2024Annual reportSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
4 · Change in ownershipDec 16, 2024Insider tradeSEC
8-K · Current reportNov 12, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedNov 6, 2024Big-stake noticeSEC
8-K · Current reportSep 13, 2024Material contractSEC
8-K · Current reportSep 5, 2024Current reportSEC
SC 13G/A · Big-stake notice, amendedSep 5, 2024Big-stake noticeSEC
4/A · Change in ownership, amendedAug 30, 2024Insider tradeSEC
4/A · Change in ownership, amendedAug 30, 2024Insider tradeSEC
4/A · Change in ownership, amendedAug 30, 2024Insider tradeSEC
4/A · Change in ownership, amendedAug 30, 2024Insider tradeSEC
8-K/A · Current report, amendedAug 26, 2024Acquisition or disposalSEC
8-K · Current reportAug 16, 2024Acquisition or disposalSEC
SC 13D · Big-stake noticeAug 16, 2024Big-stake noticeSEC
4 · Change in ownershipAug 16, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 16, 2024Insider tradeSEC
SC 13D/A · Big-stake notice, amendedAug 15, 2024Big-stake noticeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
4 · Change in ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
3 · Initial statement of ownershipAug 14, 2024Insider tradeSEC
25-NSEAug 13, 2024Other filingsSEC
10-Q · Quarterly reportAug 9, 2024Quarterly reportSEC
8-K · Current reportAug 2, 2024Management or board changeSEC
425Jul 19, 2024Other filingsSEC
8-K · Current reportJul 19, 2024Material contractSEC
SEC STAFF LETTERJul 16, 2024Other filingsSEC
EFFECT · Notice that a registration is effectiveJul 15, 2024Other filingsSEC
424B3 · ProspectusJul 12, 2024Offer documentSEC
CORRESP · Letter to the SECJul 11, 2024Other filingsSEC
S-4/A · Registration statement, amendedJul 11, 2024Offer documentSEC
S-4/A · Registration statement, amendedJul 11, 2024Offer documentSEC
425Jun 18, 2024Other filingsSEC
8-K · Current reportJun 18, 2024Material contractSEC
S-4/A · Registration statement, amendedJun 17, 2024Offer documentSEC
CORRESP · Letter to the SECJun 17, 2024Other filingsSEC
425Jun 6, 2024Other filingsSEC
8-K · Current reportJun 6, 2024Current reportSEC
8-K · Current reportMay 21, 2024Material contractSEC

This page holds 200 of 280 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Citius Oncology, Inc.’s releases · as of May 5, 2026

Common shares
105,758,982
Fully diluted
108,330,410

Fully diluted

LineSharesAs of
Common shares105,758,982
Warrants2,571,428Sep 10, 2025

Warrants and options

Lot
Warrants · US$1.09 · expire about Dec 2030
Warrants · US$1.84 · expire about Mar 2031
Warrants · US$1.32 · expire about Jul 2030

Share count over time

CountShares
Nov 22, 2026105,758,982

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Armistice Capital, LLC8.34M9.0%US$8.42MSep 30, 2026
Bank of America3.84M4.1%US$3.87MSep 30, 2026
Vanguard721K0.78%US$729KSep 30, 2026
Geode Capital282K0.30%US$285KSep 30, 2026
Citadel126K0.14%US$127KSep 30, 2026
IFP Advisors, Inc107K0.12%US$108KSep 30, 2026
PFS Signature Wealth LLC107K0.12%US$108KSep 30, 2026
Northern Trust45,7460.05%US$46,203Sep 30, 2026
State Street42,9000.05%US$43,329Sep 30, 2026
Hrt Financial LP31,2270.03%US$31,000Sep 30, 2026
All 21 holders
HolderSharesOf the companyValueAs of
Private Advisor Group, LLC25,0000.03%US$25,250Sep 30, 2026
Captrust Financial Advisors21,0000.02%US$21,210Sep 30, 2026
UBS13,9820.02%US$14,122Sep 30, 2026
StoneX Group Inc.13,7190.01%US$12,337Sep 30, 2026
Two Sigma13,0320.01%US$13,162Sep 30, 2026
Susquehanna10,6010.01%US$10,707Sep 30, 2026
Tower Research Capital LLC (TRC)3,930<0.01%US$3,969Sep 30, 2026
Osaic Holdings, Inc.1,000<0.01%US$1,010Sep 30, 2026
Wells Fargo500<0.01%US$505Sep 30, 2026
Caitong International Asset Management Co., Ltd1<0.01%US$1Sep 30, 2026
Citigroup Inc1<0.01%US$1Sep 30, 2026

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund370K0.40%US$241KJun 30, 2026
Vanguard Extended Market Index Fund176K0.19%US$115KJun 30, 2026
Fidelity Extended Market Index Fund113K0.12%US$89,962May 31, 2026
Fidelity Nasdaq Composite Index Fund57,2970.06%US$45,723May 31, 2026
Fidelity Total Market Index Fund26,2900.03%US$20,979May 31, 2026
Fidelity Series Total Market Index Fund23,3920.03%US$18,667May 31, 2026

Big stakes

StakeStakeSharesDateFiling
Citius Pharmaceuticals, Inc.71.00%66MMay 15, 2026Schedule 13D
Armistice Capital, LLC9.99%9.39MSep 30, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Dennis M. McGrath
Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Feb 7, 2023); Lucid Diagnostics Inc. (Chief Financial Officer · Since at least Oct 13, 2021); PAVmed Inc. (President and CFO · Since at least Feb 14, 2018); DarioHealth Corp. (Board Member · Since at least Oct 23, 2017)
Director · Since at least Aug 12, 2024
Leonard Mazur
Other companies: Citius Pharmaceuticals, Inc. (Co-Founder, CEO and Chairman of the Board of Directors · Since at least Mar 30, 2016); Canton Strategic Holdings, Inc. (Director · Jan 11, 2022 – Aug 9, 2024 · Past)
Chairman · Since at least Aug 12, 2024
Myron Holubiak
Other companies: Citius Pharmaceuticals, Inc. (Co-Founder, Executive Vice Chairman · Since at least Mar 28, 2018); Assembly Biosciences, Inc. (Director · May 30, 2018 – May 20, 2021 · Past)
Secretary · Since at least Aug 12, 2024
Brian Hartzband
Other companies: GMEX Robotics Corporation (President of U · Since at least Jul 1, 2026)
Director · Oct 13, 2022 – Oct 13, 2022 · Past
Carol Webb
Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
Cathy Jiang
Other companies: Peace Acquisition Corp (CFO · Since at least May 21, 2026)
Director · Oct 13, 2022 – Oct 13, 2022 · Past
Eugene Holuka
Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Oct 6, 2020)
Director · Since at least Aug 12, 2024
Jaime Bartushak
Other companies: Citius Pharmaceuticals, Inc. (Chief Financial Officer & Chief Business Officer · Since at least Oct 6, 2020)
Chief Financial Officer · Since at least Aug 12, 2024
Joel Mayersohn
Other companies: Peace Acquisition Corp (Director · Since at least May 21, 2026)
Director · Since at least Dec 12, 2024
Myron S. Czuczman
Other companies: Citius Pharmaceuticals, Inc. (Chief Medical Officer and EVP · Since at least Jul 14, 2020)
Chief Medical Officer · Since at least Aug 12, 2024
All 13 people
PersonSeat
Robert Smith
Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Mar 12, 2024)
Director · Since at least Aug 12, 2024
Suren Dutia
Other companies: Citius Pharmaceuticals, Inc. (Director · Since at least Nov 5, 2026)
Director · Since at least Nov 5, 2026
Jonathan PeriDirector · Since at least Aug 10, 2026

Open People

Log in to ask 6ix AI your own questions about Citius Oncology, Inc.